Idenix, Inc starts recruiting phase I, double-blind, multiple-dose study to evaluate the pharmacokinetic drug-drug interaction between it's protease inhibitior IDX320 and it's polymerase inhibitor IDX184 in healthy subjects
More info here: http://bit.ly/dlDQdC
Subscribe to:
Post Comments (Atom)
Posts
On paper, this looks like a good synergistic combination. Both QD drugs, mild AE's and synergistic activity in vitro. IDX320 looks pretty clean from a DDI standpoint and, as we've learned from the HIV days, DDI's (or rather, the lack thereof) are going to be hugely important. Also, the combo of a PI and a nucleotide inhibitor, in theory, should have a higher barrier of resistance than a PI and a non-nuc, the non-nuc having a lower barrier of resistance in that combination.
ReplyDelete